Skip to Main Content
Try STAT+ TODAY
Trending:
Health
First Opinion
Biotech
Coronavirus
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

A conversation with Exuma Biotech’s CEO about CAR-T and China’s strategic advantages

By Jonathan Chan Oct. 20, 2020

Reprints

This is part of an occasional series of brief Q&As with pharma newsmakers in China. This week we talked to Gregory Frost, chairman and CEO of Exuma Biotech.

What is Exuma Biotech’s origin story and why did you decide to found this company?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Jonathan Chan

China Health Care Writer

Tags

I was laid off from a public health job.…
I was laid off from a public health job. Trust me, tech layoffs are different
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Turkish court hands Novartis and Roche a rare win…
Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye…
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: ALS Association and its chapters battle over money…
Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links…
They were the 10% left out of life-changing treatments.…
They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally…

Recommended Stories